Evaluating the synergism between sildenafil and metformin in an animal model of diabetic neuropathy induced by alloxan
Abstract
Given the complex mechanism of diabetic neuropathy, evaluating the effect of drug combinations in this pathology is of an utmost importance.The aim of this study was to evaluate the synergism between sildenafil and metformin in an alloxan induced diabetic neuropathy mouse model.The pain latency times obtained for male mice in the cold and heat hypersensitivity tests, as well as the administered drug doses were processed and analysed in Python Programming Language by using the Multidimensional Synergy of Combinations algorithm, with the computation of three drug synergy indicator types, based on efficacy, potency and cooperativity.The results showed mixed values in terms of the synergism and antagonism between sildenafil and metformin on neuropathic pain, but drug synergy was identified for at least one indicator for all experimental tests.While this study is the first to evaluate the synergism between sildenafil and metformin on diabetic neuropathy, future studies must aim in analysing a higher number of drug doses, with the development of a model which might be translated to clinical data. RezumatȚinând cont de mecanismul complex de declanșare a neuropatiei diabetice, este extrem de importantă evaluarea efectului combinațiilor medicamentoase în tratarea acestei patologii.Astfel, obiectivul principal al acestui studiu a fost reprezentat de evaluarea sinergismului dintre sildenafil și metformin într-un model animal de neuropatie diabetică indusă de aloxan.Timpii obținuți…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.